Which has preferable valuation and earnings, PLSE or PEN?

Penumbra has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 10,063.71 -$72.78M -$1.18 N/A Penumbra $1.50B 8.30 $177.69M $4.07 77.89

Does the media prefer PLSE or PEN?

In the previous week, Pulse Biosciences had 3 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Pulse Biosciences and 1 mentions for Penumbra. Pulse Biosciences' average media sentiment score of 0.72 beat Penumbra's score of 0.29 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BAX or PLSE?

In the previous week, Baxter International had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 9 mentions for Baxter International and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat Baxter International's score of -0.32 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PLSE or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Pulse Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 10,063.71 -$72.78M -$1.18 N/A Smith & Nephew SNATS $6.16B 1.83 $625M N/A N/A

Does the media favor PLSE or SNN?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Smith & Nephew SNATS and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat Smith & Nephew SNATS's score of -0.01 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to GMED or PLSE?

In the previous week, Globus Medical and Globus Medical both had 4 articles in the media. Pulse Biosciences' average media sentiment score of 0.72 beat Globus Medical's score of 0.28 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PLSE or GKOS more profitable?

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences -6,755.78% -94.42% -79.96% Glaukos -30.68% -6.37% -4.78%

Does the media prefer PLSE or GKOS?

In the previous week, Pulse Biosciences had 2 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for Pulse Biosciences and 2 mentions for Glaukos. Pulse Biosciences' average media sentiment score of 0.72 beat Glaukos' score of 0.28 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pulse Biosciences (PLSE) Competitors

$48.72 -1.03 (-2.06%)

As of 12:42 PM Eastern

Compare

PLSE vs. PEN, BAX, SNN, GMED, and GKOS

Should you buy Pulse Biosciences stock or one of its competitors? Pulse Biosciences's main competitors and comparable companies include Penumbra (PEN), Baxter International (BAX), Smith & Nephew SNATS (SNN), Globus Medical (GMED), and Glaukos (GKOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulse Biosciences compare to Penumbra?

Pulse Biosciences (NASDAQ:PLSE) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Pulse Biosciences currently has a consensus target price of $53.20, indicating a potential upside of 6.93%. Penumbra has a consensus target price of $367.07, indicating a potential upside of 15.80%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has a net margin of 10.67% compared to Pulse Biosciences' net margin of -6,755.78%. Penumbra's return on equity of 10.50% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Penumbra	10.67%	10.50%	8.17%

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pulse Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Penumbra has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,063.71	-$72.78M	-$1.18	N/A
Penumbra	$1.50B	8.30	$177.69M	$4.07	77.89

In the previous week, Pulse Biosciences had 3 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Pulse Biosciences and 1 mentions for Penumbra. Pulse Biosciences' average media sentiment score of 0.72 beat Penumbra's score of 0.29 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Penumbra beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Baxter International?

Baxter International (NYSE:BAX) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Baxter International presently has a consensus price target of $22.36, indicating a potential downside of 8.00%. Pulse Biosciences has a consensus price target of $53.20, indicating a potential upside of 6.93%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Pulse Biosciences has lower revenue, but higher earnings than Baxter International. Pulse Biosciences is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.47B	1.10	-$957M	-$2.07	N/A
Pulse Biosciences	$350K	10,063.71	-$72.78M	-$1.18	N/A

Baxter International has a net margin of -9.27% compared to Pulse Biosciences' net margin of -6,755.78%. Baxter International's return on equity of 16.57% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.27%	16.57%	5.24%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Baxter International has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

90.2% of Baxter International shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Baxter International had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 9 mentions for Baxter International and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat Baxter International's score of -0.32 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pulse Biosciences beats Baxter International on 10 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Pulse Biosciences (NASDAQ:PLSE) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Smith & Nephew SNATS and 4 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.72 beat Smith & Nephew SNATS's score of -0.01 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has higher revenue and earnings than Pulse Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,063.71	-$72.78M	-$1.18	N/A
Smith & Nephew SNATS	$6.16B	1.83	$625M	N/A	N/A

Pulse Biosciences presently has a consensus price target of $53.20, indicating a potential upside of 6.93%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 18.82%. Given Smith & Nephew SNATS's higher possible upside, analysts clearly believe Smith & Nephew SNATS is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Smith & Nephew SNATS has a net margin of 0.00% compared to Pulse Biosciences' net margin of -6,755.78%. Smith & Nephew SNATS's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Smith & Nephew SNATS	N/A	N/A	N/A

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pulse Biosciences has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Summary

Pulse Biosciences beats Smith & Nephew SNATS on 8 of the 15 factors compared between the two stocks.

How does Pulse Biosciences compare to Globus Medical?

Globus Medical (NYSE:GMED) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Globus Medical and Globus Medical both had 4 articles in the media. Pulse Biosciences' average media sentiment score of 0.72 beat Globus Medical's score of 0.28 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical presently has a consensus target price of $99.46, indicating a potential upside of 30.23%. Pulse Biosciences has a consensus target price of $53.20, indicating a potential upside of 6.93%. Given Globus Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Globus Medical is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Globus Medical has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Globus Medical has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.49	$537.87M	$3.91	19.53
Pulse Biosciences	$350K	10,063.71	-$72.78M	-$1.18	N/A

Globus Medical has a net margin of 17.02% compared to Pulse Biosciences' net margin of -6,755.78%. Globus Medical's return on equity of 14.57% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Summary

Globus Medical beats Pulse Biosciences on 12 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Glaukos?

Pulse Biosciences (NASDAQ:PLSE) and Glaukos (NYSE:GKOS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pulse Biosciences has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,063.71	-$72.78M	-$1.18	N/A
Glaukos	$612.84M	15.60	-$187.69M	-$3.25	N/A

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Glaukos	-30.68%	-6.37%	-4.78%

Pulse Biosciences presently has a consensus price target of $53.20, suggesting a potential upside of 6.93%. Glaukos has a consensus price target of $180.54, suggesting a potential upside of 11.39%. Given Glaukos' higher probable upside, analysts plainly believe Glaukos is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Pulse Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Pulse Biosciences had 2 more articles in the media than Glaukos. MarketBeat recorded 4 mentions for Pulse Biosciences and 2 mentions for Glaukos. Pulse Biosciences' average media sentiment score of 0.72 beat Glaukos' score of 0.28 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pulse Biosciences beats Glaukos on 10 of the 17 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.49B	$5.48B	$7.24B	$13.35B
Dividend Yield	N/A	1.78%	2.53%	17.39%
P/E Ratio	-41.79	25.46	274.58	26.17
Price / Sales	9,960.55	82.23	632.90	107.74
Price / Cash	N/A	32.45	79.41	53.24
Price / Book	41.38	5.99	10.87	6.30
Net Income	-$72.78M	$147.52M	$3.50B	$381.95M
7 Day Performance	-1.36%	-0.15%	-1.13%	-0.80%
1 Month Performance	-7.51%	-4.74%	-6.30%	-5.26%
1 Year Performance	147.81%	1.87%	6.42%	0.89%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	2.8697 of 5 stars	$48.73 -2.1%	$53.20 +9.2%	+155.8%	$3.45B	$350K	N/A	116	Analyst Forecast
PEN Penumbra	2.5865 of 5 stars	$318.76 -0.1%	$367.07 +15.2%	+24.1%	$12.57B	$1.40B	78.32	4,700
BAX Baxter International	1.0533 of 5 stars	$23.50 +0.0%	$22.45 -4.4%	+5.0%	$12.14B	$11.24B	N/A	37,500	News Coverage Analyst Forecast
SNN Smith & Nephew SNATS	3.3581 of 5 stars	$26.93 -0.6%	$31.91 +18.5%	-25.3%	$11.37B	$6.16B	N/A	18,362
GMED Globus Medical	4.1075 of 5 stars	$75.74 +1.3%	$101.77 +34.4%	+26.9%	$10.04B	$2.94B	19.37	6,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. PEN, BAX, SNN, GMED, and GKOS

How does Pulse Biosciences compare to Penumbra?

Summary

How does Pulse Biosciences compare to Baxter International?

Summary

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Summary

How does Pulse Biosciences compare to Globus Medical?

Summary

How does Pulse Biosciences compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. PEN, BAX, SNN, GMED, and GKOS

How does Pulse Biosciences compare to Penumbra?

Do analysts prefer PLSE or PEN?

Is PLSE or PEN more profitable?

Do insiders & institutionals hold more shares of PLSE or PEN?

Which has more volatility and risk, PLSE or PEN?

Which has preferable valuation and earnings, PLSE or PEN?

Does the media prefer PLSE or PEN?

Summary

How does Pulse Biosciences compare to Baxter International?

Do analysts recommend BAX or PLSE?

Which has preferable earnings & valuation, BAX or PLSE?

Is BAX or PLSE more profitable?

Which has more volatility & risk, BAX or PLSE?

Do institutionals and insiders believe in BAX or PLSE?

Does the media refer more to BAX or PLSE?

Summary

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Does the media favor PLSE or SNN?

Which has higher earnings & valuation, PLSE or SNN?

Do analysts prefer PLSE or SNN?

Is PLSE or SNN more profitable?

Do institutionals & insiders hold more shares of PLSE or SNN?

Which has more volatility and risk, PLSE or SNN?

Summary

How does Pulse Biosciences compare to Globus Medical?

Do insiders & institutionals believe in GMED or PLSE?

Does the media refer more to GMED or PLSE?

Do analysts prefer GMED or PLSE?

Which has more risk & volatility, GMED or PLSE?

Which has stronger valuation & earnings, GMED or PLSE?

Is GMED or PLSE more profitable?

Summary

How does Pulse Biosciences compare to Glaukos?

Do institutionals and insiders hold more shares of PLSE or GKOS?

Which has higher valuation & earnings, PLSE or GKOS?

Is PLSE or GKOS more profitable?

Do analysts rate PLSE or GKOS?

Which has more risk & volatility, PLSE or GKOS?

Does the media prefer PLSE or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools